 Jayashree Kalpathy-Cramer
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 32 | 2023 | 111 | 5.800 |
Why?
| | Artificial Intelligence | 28 | 2024 | 144 | 4.470 |
Why?
| | Brain Neoplasms | 23 | 2024 | 979 | 3.700 |
Why?
| | Glioblastoma | 15 | 2024 | 253 | 3.570 |
Why?
| | Image Processing, Computer-Assisted | 21 | 2024 | 685 | 3.290 |
Why?
| | Algorithms | 36 | 2024 | 1470 | 2.460 |
Why?
| | Machine Learning | 19 | 2023 | 316 | 2.440 |
Why?
| | Diagnostic Imaging | 18 | 2022 | 275 | 2.360 |
Why?
| | Natural Language Processing | 7 | 2023 | 72 | 2.090 |
Why?
| | Magnetic Resonance Imaging | 39 | 2024 | 3053 | 1.960 |
Why?
| | Information Storage and Retrieval | 8 | 2015 | 106 | 1.840 |
Why?
| | Radiology | 8 | 2023 | 141 | 1.710 |
Why?
| | Glioma | 8 | 2022 | 294 | 1.660 |
Why?
| | Neuroimaging | 7 | 2022 | 249 | 1.660 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2024 | 216 | 1.450 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 5 | 2016 | 117 | 1.380 |
Why?
| | Software | 9 | 2020 | 530 | 1.210 |
Why?
| | Image Interpretation, Computer-Assisted | 12 | 2019 | 223 | 1.120 |
Why?
| | Papillomavirus Infections | 4 | 2024 | 261 | 1.070 |
Why?
| | Tomography, X-Ray Computed | 15 | 2023 | 2286 | 1.030 |
Why?
| | Humans | 143 | 2024 | 114709 | 1.000 |
Why?
| | Telemedicine | 7 | 2023 | 662 | 0.980 |
Why?
| | ROC Curve | 13 | 2022 | 442 | 0.850 |
Why?
| | Ophthalmology | 5 | 2023 | 77 | 0.850 |
Why?
| | Privacy | 1 | 2023 | 28 | 0.850 |
Why?
| | Radiology Information Systems | 4 | 2022 | 25 | 0.840 |
Why?
| | Retina | 6 | 2023 | 263 | 0.840 |
Why?
| | Solitary Pulmonary Nodule | 3 | 2021 | 21 | 0.840 |
Why?
| | Severity of Illness Index | 8 | 2021 | 2540 | 0.830 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2018 | 36 | 0.820 |
Why?
| | Infant, Newborn | 32 | 2023 | 5047 | 0.780 |
Why?
| | Reproducibility of Results | 26 | 2023 | 2765 | 0.750 |
Why?
| | Ophthalmoscopy | 7 | 2023 | 30 | 0.700 |
Why?
| | Crowdsourcing | 1 | 2020 | 14 | 0.700 |
Why?
| | Breast Neoplasms | 5 | 2024 | 1862 | 0.690 |
Why?
| | Medicine | 1 | 2021 | 102 | 0.680 |
Why?
| | Gestational Age | 15 | 2023 | 760 | 0.650 |
Why?
| | Stroke | 3 | 2023 | 1022 | 0.630 |
Why?
| | Retinal Vessels | 5 | 2020 | 50 | 0.620 |
Why?
| | Retinal Vein | 4 | 2021 | 13 | 0.590 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2017 | 38 | 0.580 |
Why?
| | Lung Neoplasms | 5 | 2021 | 2177 | 0.560 |
Why?
| | Sensitivity and Specificity | 13 | 2023 | 1694 | 0.560 |
Why?
| | Databases, Factual | 8 | 2021 | 1125 | 0.550 |
Why?
| | Retrospective Studies | 23 | 2023 | 12556 | 0.540 |
Why?
| | Radiologists | 3 | 2022 | 35 | 0.540 |
Why?
| | Tumor Burden | 4 | 2023 | 259 | 0.530 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 103 | 0.530 |
Why?
| | Peripheral Arterial Disease | 4 | 2023 | 380 | 0.520 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 82 | 0.520 |
Why?
| | Quinolines | 1 | 2016 | 129 | 0.510 |
Why?
| | Gallbladder Neoplasms | 3 | 2011 | 11 | 0.510 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 859 | 0.490 |
Why?
| | Radiography, Thoracic | 5 | 2022 | 150 | 0.490 |
Why?
| | Pattern Recognition, Automated | 5 | 2023 | 67 | 0.480 |
Why?
| | Benchmarking | 6 | 2024 | 161 | 0.480 |
Why?
| | Delivery of Health Care | 1 | 2021 | 833 | 0.470 |
Why?
| | Female | 50 | 2024 | 59523 | 0.470 |
Why?
| | Chemoradiotherapy | 6 | 2018 | 188 | 0.460 |
Why?
| | Subtraction Technique | 1 | 2014 | 24 | 0.460 |
Why?
| | White Matter | 3 | 2023 | 105 | 0.460 |
Why?
| | Radiation Oncology | 2 | 2014 | 75 | 0.450 |
Why?
| | Photography | 6 | 2021 | 89 | 0.450 |
Why?
| | Retinal Artery | 3 | 2021 | 15 | 0.450 |
Why?
| | Vocabulary, Controlled | 1 | 2014 | 41 | 0.450 |
Why?
| | Fundus Oculi | 4 | 2023 | 40 | 0.440 |
Why?
| | Phantoms, Imaging | 7 | 2023 | 123 | 0.440 |
Why?
| | Multimodal Imaging | 1 | 2014 | 88 | 0.440 |
Why?
| | Datasets as Topic | 5 | 2021 | 100 | 0.400 |
Why?
| | Clinical Competence | 2 | 2016 | 893 | 0.400 |
Why?
| | Male | 47 | 2024 | 55609 | 0.400 |
Why?
| | Survival Analysis | 4 | 2016 | 1211 | 0.390 |
Why?
| | Contrast Media | 9 | 2020 | 345 | 0.390 |
Why?
| | Internet | 2 | 2014 | 596 | 0.380 |
Why?
| | Cerebral Blood Volume | 3 | 2020 | 4 | 0.380 |
Why?
| | Radiotherapy, Conformal | 1 | 2011 | 68 | 0.380 |
Why?
| | Brain | 8 | 2021 | 2371 | 0.370 |
Why?
| | Adrenoleukodystrophy | 2 | 2023 | 4 | 0.360 |
Why?
| | Proportional Hazards Models | 4 | 2011 | 1075 | 0.360 |
Why?
| | Head and Neck Neoplasms | 5 | 2020 | 427 | 0.350 |
Why?
| | Middle Aged | 27 | 2024 | 26738 | 0.340 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 2 | 2023 | 98 | 0.340 |
Why?
| | Aged | 26 | 2024 | 19074 | 0.340 |
Why?
| | Medical Informatics | 4 | 2020 | 90 | 0.340 |
Why?
| | Endovascular Procedures | 2 | 2023 | 269 | 0.310 |
Why?
| | Database Management Systems | 1 | 2008 | 47 | 0.310 |
Why?
| | User-Computer Interface | 4 | 2015 | 140 | 0.300 |
Why?
| | Early Detection of Cancer | 4 | 2024 | 328 | 0.300 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 182 | 0.300 |
Why?
| | Adult | 25 | 2024 | 30554 | 0.300 |
Why?
| | Lung | 6 | 2022 | 3561 | 0.300 |
Why?
| | Prognosis | 9 | 2024 | 3330 | 0.290 |
Why?
| | Automation | 5 | 2020 | 74 | 0.290 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2018 | 83 | 0.260 |
Why?
| | Mass Screening | 3 | 2023 | 1006 | 0.260 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1879 | 0.260 |
Why?
| | Radiography | 5 | 2022 | 812 | 0.260 |
Why?
| | Rectal Neoplasms | 2 | 2021 | 121 | 0.250 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2007 | 203 | 0.250 |
Why?
| | Neonatal Screening | 4 | 2023 | 152 | 0.250 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2015 | 38 | 0.250 |
Why?
| | Reference Standards | 7 | 2021 | 159 | 0.230 |
Why?
| | Observer Variation | 3 | 2018 | 296 | 0.230 |
Why?
| | Forecasting | 3 | 2019 | 330 | 0.230 |
Why?
| | Adenocarcinoma in Situ | 1 | 2023 | 1 | 0.230 |
Why?
| | Cervix Uteri | 1 | 2023 | 45 | 0.220 |
Why?
| | Postoperative Care | 2 | 2019 | 222 | 0.220 |
Why?
| | Prostatic Neoplasms | 3 | 2020 | 921 | 0.220 |
Why?
| | Infant, Premature | 7 | 2023 | 476 | 0.220 |
Why?
| | Mammography | 2 | 2023 | 105 | 0.220 |
Why?
| | Imaging, Three-Dimensional | 4 | 2023 | 512 | 0.220 |
Why?
| | Uterine Cervical Dysplasia | 1 | 2023 | 42 | 0.220 |
Why?
| | Statistics as Topic | 2 | 2014 | 292 | 0.210 |
Why?
| | Oxygen | 2 | 2021 | 854 | 0.210 |
Why?
| | Ranibizumab | 1 | 2023 | 18 | 0.210 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2016 | 124 | 0.210 |
Why?
| | Diagnosis, Computer-Assisted | 2 | 2021 | 64 | 0.210 |
Why?
| | Documentation | 2 | 2015 | 167 | 0.210 |
Why?
| | Long QT Syndrome | 1 | 2023 | 59 | 0.210 |
Why?
| | Neovascularization, Pathologic | 3 | 2024 | 281 | 0.200 |
Why?
| | Biomarkers | 4 | 2018 | 3408 | 0.200 |
Why?
| | Rheumatic Diseases | 1 | 2022 | 49 | 0.200 |
Why?
| | Cohort Studies | 6 | 2022 | 4895 | 0.200 |
Why?
| | Computer Communication Networks | 2 | 2020 | 32 | 0.200 |
Why?
| | Quality Assurance, Health Care | 2 | 2014 | 311 | 0.200 |
Why?
| | Diverticulitis | 1 | 2021 | 7 | 0.190 |
Why?
| | Neoplasms | 5 | 2020 | 2097 | 0.190 |
Why?
| | Racism | 1 | 2023 | 102 | 0.190 |
Why?
| | Hospital Units | 1 | 2021 | 23 | 0.180 |
Why?
| | Infant | 10 | 2023 | 7964 | 0.180 |
Why?
| | Intestinal Obstruction | 1 | 2021 | 40 | 0.180 |
Why?
| | Biomarkers, Tumor | 3 | 2016 | 1040 | 0.180 |
Why?
| | India | 1 | 2021 | 134 | 0.180 |
Why?
| | Musculoskeletal System | 1 | 2021 | 43 | 0.180 |
Why?
| | Neoplasm Grading | 2 | 2020 | 242 | 0.180 |
Why?
| | Breast Density | 1 | 2020 | 3 | 0.180 |
Why?
| | Tibial Meniscus Injuries | 1 | 2021 | 43 | 0.180 |
Why?
| | Dacarbazine | 3 | 2015 | 99 | 0.180 |
Why?
| | Precision Medicine | 2 | 2016 | 337 | 0.180 |
Why?
| | Biomedical Research | 2 | 2019 | 585 | 0.180 |
Why?
| | Cerebellar Neoplasms | 1 | 2022 | 130 | 0.170 |
Why?
| | Microcirculation | 2 | 2017 | 135 | 0.170 |
Why?
| | Perfusion Imaging | 1 | 2020 | 51 | 0.170 |
Why?
| | Health Information Exchange | 1 | 2020 | 12 | 0.170 |
Why?
| | Radiometry | 1 | 2020 | 42 | 0.170 |
Why?
| | Lung Injury | 1 | 2022 | 198 | 0.170 |
Why?
| | Brain Ischemia | 1 | 2023 | 299 | 0.170 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2023 | 520 | 0.170 |
Why?
| | Hyperemia | 1 | 2020 | 45 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2015 | 577 | 0.170 |
Why?
| | Medical Records Systems, Computerized | 2 | 2013 | 88 | 0.170 |
Why?
| | Medulloblastoma | 1 | 2022 | 172 | 0.170 |
Why?
| | Predictive Value of Tests | 3 | 2021 | 1796 | 0.170 |
Why?
| | Appendicitis | 1 | 2021 | 114 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 638 | 0.170 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 63 | 0.170 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2017 | 133 | 0.170 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 663 | 0.170 |
Why?
| | Risk Factors | 8 | 2023 | 8634 | 0.170 |
Why?
| | Area Under Curve | 4 | 2021 | 274 | 0.170 |
Why?
| | Brain Diseases | 1 | 2021 | 125 | 0.170 |
Why?
| | Low Back Pain | 1 | 2021 | 95 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 498 | 0.160 |
Why?
| | Blood-Brain Barrier | 2 | 2017 | 106 | 0.160 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2018 | 68 | 0.160 |
Why?
| | Capillary Permeability | 1 | 2019 | 139 | 0.160 |
Why?
| | Aneurysm, Ruptured | 1 | 2019 | 34 | 0.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1356 | 0.160 |
Why?
| | Age Determination by Skeleton | 1 | 2018 | 16 | 0.160 |
Why?
| | Prospective Studies | 7 | 2023 | 6220 | 0.160 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 215 | 0.160 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2018 | 25 | 0.160 |
Why?
| | Treatment Outcome | 7 | 2023 | 9088 | 0.150 |
Why?
| | Linear Models | 1 | 2021 | 768 | 0.150 |
Why?
| | Global Health | 1 | 2021 | 287 | 0.150 |
Why?
| | Intracranial Aneurysm | 1 | 2019 | 91 | 0.150 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 217 | 0.150 |
Why?
| | Arteries | 2 | 2019 | 247 | 0.150 |
Why?
| | Medical Record Linkage | 1 | 2018 | 53 | 0.150 |
Why?
| | Bayes Theorem | 2 | 2016 | 329 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1342 | 0.140 |
Why?
| | Chronic Pain | 1 | 2021 | 210 | 0.140 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 290 | 0.140 |
Why?
| | Preoperative Period | 1 | 2017 | 103 | 0.140 |
Why?
| | Patient Readmission | 1 | 2022 | 610 | 0.140 |
Why?
| | Gadolinium | 1 | 2017 | 73 | 0.140 |
Why?
| | Polysaccharides, Bacterial | 1 | 2017 | 66 | 0.140 |
Why?
| | Gray Matter | 1 | 2018 | 67 | 0.140 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 638 | 0.140 |
Why?
| | Skin Diseases, Genetic | 1 | 2016 | 10 | 0.130 |
Why?
| | Pharyngeal Muscles | 1 | 2016 | 3 | 0.130 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2016 | 13 | 0.130 |
Why?
| | SEER Program | 3 | 2011 | 196 | 0.130 |
Why?
| | Patient-Specific Modeling | 1 | 2016 | 36 | 0.130 |
Why?
| | Blood Vessels | 1 | 2017 | 180 | 0.130 |
Why?
| | Liver Cirrhosis | 1 | 2017 | 227 | 0.130 |
Why?
| | Aged, 80 and over | 5 | 2018 | 6347 | 0.130 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 430 | 0.130 |
Why?
| | Angiogenesis Inhibitors | 2 | 2016 | 214 | 0.130 |
Why?
| | Models, Biological | 3 | 2019 | 1621 | 0.130 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2020 | 40 | 0.130 |
Why?
| | Vascular Malformations | 1 | 2016 | 47 | 0.130 |
Why?
| | Blood Volume Determination | 1 | 2015 | 5 | 0.130 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2387 | 0.130 |
Why?
| | Fibrosis | 1 | 2017 | 453 | 0.120 |
Why?
| | Positron-Emission Tomography | 4 | 2021 | 259 | 0.120 |
Why?
| | Cranial Irradiation | 1 | 2015 | 66 | 0.120 |
Why?
| | Birth Weight | 3 | 2023 | 440 | 0.120 |
Why?
| | Physical Phenomena | 1 | 2014 | 12 | 0.120 |
Why?
| | Radiation Injuries | 1 | 2016 | 128 | 0.120 |
Why?
| | Organs at Risk | 1 | 2014 | 30 | 0.120 |
Why?
| | Brachial Plexus | 1 | 2014 | 28 | 0.120 |
Why?
| | Administration, Oral | 1 | 2016 | 728 | 0.120 |
Why?
| | Mutation | 3 | 2024 | 3346 | 0.120 |
Why?
| | Young Adult | 7 | 2018 | 10472 | 0.120 |
Why?
| | Deglutition Disorders | 1 | 2016 | 118 | 0.120 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2011 | 40 | 0.110 |
Why?
| | Joint Instability | 1 | 2016 | 162 | 0.110 |
Why?
| | Arteriovenous Malformations | 1 | 2013 | 24 | 0.110 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 62 | 0.110 |
Why?
| | Optic Disk | 1 | 2013 | 38 | 0.110 |
Why?
| | Computer Literacy | 1 | 2013 | 6 | 0.110 |
Why?
| | Health Information Systems | 1 | 2013 | 16 | 0.100 |
Why?
| | Survival Rate | 3 | 2018 | 1644 | 0.100 |
Why?
| | Terminology as Topic | 1 | 2014 | 187 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2014 | 740 | 0.100 |
Why?
| | Risk Assessment | 3 | 2023 | 2968 | 0.100 |
Why?
| | Computer Simulation | 4 | 2017 | 873 | 0.100 |
Why?
| | Research Design | 2 | 2014 | 928 | 0.100 |
Why?
| | Workload | 1 | 2013 | 132 | 0.100 |
Why?
| | Otorhinolaryngologic Neoplasms | 1 | 2011 | 2 | 0.100 |
Why?
| | Nomograms | 1 | 2011 | 41 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1473 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 1820 | 0.090 |
Why?
| | Support Vector Machine | 2 | 2021 | 34 | 0.090 |
Why?
| | Exercise | 1 | 2020 | 1644 | 0.090 |
Why?
| | Liver | 1 | 2017 | 1637 | 0.090 |
Why?
| | North America | 2 | 2021 | 256 | 0.080 |
Why?
| | Periodicals as Topic | 1 | 2012 | 181 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2023 | 101 | 0.080 |
Why?
| | Lower Extremity | 2 | 2023 | 335 | 0.080 |
Why?
| | Child | 7 | 2022 | 18422 | 0.080 |
Why?
| | Oregon | 1 | 2008 | 66 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2024 | 4411 | 0.080 |
Why?
| | Total Quality Management | 1 | 2008 | 61 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2015 | 800 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 785 | 0.070 |
Why?
| | MEDLINE | 1 | 2008 | 22 | 0.070 |
Why?
| | Breast | 2 | 2019 | 139 | 0.070 |
Why?
| | Dilatation, Pathologic | 2 | 2018 | 55 | 0.070 |
Why?
| | Monte Carlo Method | 2 | 2017 | 138 | 0.070 |
Why?
| | United States | 4 | 2020 | 12186 | 0.070 |
Why?
| | Cluster Analysis | 1 | 2007 | 455 | 0.070 |
Why?
| | Clinical Protocols | 2 | 2019 | 233 | 0.060 |
Why?
| | Critical Illness | 2 | 2021 | 646 | 0.060 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 176 | 0.060 |
Why?
| | Physicians | 1 | 2013 | 772 | 0.060 |
Why?
| | Kinetics | 2 | 2019 | 1551 | 0.060 |
Why?
| | Colposcopy | 1 | 2023 | 15 | 0.060 |
Why?
| | Brain Infarction | 1 | 2023 | 22 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 49 | 0.050 |
Why?
| | Bias | 2 | 2014 | 179 | 0.050 |
Why?
| | DNA Helicases | 1 | 2024 | 133 | 0.050 |
Why?
| | Models, Theoretical | 2 | 2021 | 515 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 30 | 0.050 |
Why?
| | Data Curation | 1 | 2022 | 11 | 0.050 |
Why?
| | Smartphone | 1 | 2023 | 73 | 0.050 |
Why?
| | Logistic Models | 2 | 2021 | 1841 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2022 | 66 | 0.050 |
Why?
| | Vagina | 1 | 2024 | 146 | 0.050 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2024 | 152 | 0.050 |
Why?
| | Quinazolines | 2 | 2013 | 240 | 0.050 |
Why?
| | Health Services | 1 | 2022 | 103 | 0.050 |
Why?
| | Limb Salvage | 1 | 2022 | 52 | 0.050 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 304 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3004 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2023 | 257 | 0.050 |
Why?
| | Receptors, GABA | 1 | 2021 | 8 | 0.050 |
Why?
| | Utilization Review | 1 | 2021 | 34 | 0.050 |
Why?
| | Edema | 1 | 2022 | 119 | 0.050 |
Why?
| | Nepal | 1 | 2021 | 20 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 932 | 0.050 |
Why?
| | Seizures | 1 | 2024 | 340 | 0.050 |
Why?
| | Incidence | 2 | 2020 | 2313 | 0.050 |
Why?
| | Massachusetts | 1 | 2021 | 134 | 0.050 |
Why?
| | Abdomen | 1 | 2021 | 99 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2021 | 217 | 0.040 |
Why?
| | Models, Statistical | 2 | 2016 | 599 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2381 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 551 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 143 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2023 | 343 | 0.040 |
Why?
| | Ankle | 1 | 2020 | 70 | 0.040 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 4 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2024 | 591 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 635 | 0.040 |
Why?
| | Arthroscopy | 1 | 2021 | 200 | 0.040 |
Why?
| | Medical Oncology | 1 | 2021 | 229 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 125 | 0.040 |
Why?
| | Bevacizumab | 1 | 2019 | 115 | 0.040 |
Why?
| | Hand Bones | 1 | 2018 | 2 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 250 | 0.040 |
Why?
| | Risk | 1 | 2021 | 812 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 144 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 41 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 743 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2019 | 121 | 0.040 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 149 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 539 | 0.040 |
Why?
| | Hemizygote | 1 | 2017 | 3 | 0.040 |
Why?
| | Carbon Tetrachloride | 1 | 2017 | 6 | 0.040 |
Why?
| | Ecosystem | 1 | 2022 | 502 | 0.040 |
Why?
| | Outpatients | 1 | 2021 | 326 | 0.040 |
Why?
| | Half-Life | 1 | 2017 | 141 | 0.040 |
Why?
| | Skull | 1 | 2018 | 119 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 332 | 0.040 |
Why?
| | Diffusion | 1 | 2017 | 119 | 0.040 |
Why?
| | Permeability | 1 | 2017 | 149 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 75 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2021 | 529 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2017 | 286 | 0.040 |
Why?
| | Societies, Medical | 1 | 2021 | 664 | 0.030 |
Why?
| | Information Dissemination | 1 | 2019 | 186 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2016 | 56 | 0.030 |
Why?
| | Expert Systems | 1 | 2016 | 3 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 617 | 0.030 |
Why?
| | Prostate | 1 | 2017 | 156 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1528 | 0.030 |
Why?
| | Perfusion | 1 | 2016 | 148 | 0.030 |
Why?
| | Video Recording | 1 | 2017 | 143 | 0.030 |
Why?
| | Palate, Soft | 1 | 2016 | 10 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 712 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 127 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 220 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1214 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 167 | 0.030 |
Why?
| | Antineoplastic Protocols | 1 | 2015 | 1 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2017 | 221 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 81 | 0.030 |
Why?
| | Molecular Imaging | 1 | 2016 | 50 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 244 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 63 | 0.030 |
Why?
| | Motion | 1 | 2015 | 91 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 620 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1448 | 0.030 |
Why?
| | Child, Preschool | 2 | 2018 | 9119 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2014 | 32 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 633 | 0.030 |
Why?
| | Image Enhancement | 1 | 2015 | 159 | 0.030 |
Why?
| | Carcinoma | 1 | 2016 | 198 | 0.030 |
Why?
| | Adolescent | 3 | 2018 | 17855 | 0.030 |
Why?
| | DNA Modification Methylases | 1 | 2013 | 14 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 22 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1320 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2015 | 195 | 0.030 |
Why?
| | Fluorescein Angiography | 1 | 2013 | 102 | 0.030 |
Why?
| | Argentina | 1 | 2013 | 14 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 347 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4410 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 385 | 0.030 |
Why?
| | Smoking | 1 | 2019 | 1383 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 1752 | 0.020 |
Why?
| | Hemodynamics | 1 | 2016 | 1012 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 5520 | 0.020 |
Why?
| | Time Factors | 1 | 2022 | 6116 | 0.020 |
Why?
| | Life Tables | 1 | 2011 | 17 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 226 | 0.020 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2011 | 12 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 282 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 797 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 900 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1056 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1373 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 993 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 412 | 0.020 |
Why?
| | Probability | 1 | 2011 | 289 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2011 | 275 | 0.020 |
Why?
| | Rats | 1 | 2017 | 4958 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 811 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 634 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 3535 | 0.020 |
Why?
| | PubMed | 1 | 2008 | 10 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1167 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 975 | 0.020 |
Why?
| | Internship and Residency | 1 | 2014 | 926 | 0.020 |
Why?
| | Age Factors | 1 | 2011 | 2894 | 0.010 |
Why?
| | Mice | 1 | 2017 | 14872 | 0.010 |
Why?
| | Animals | 1 | 2017 | 31709 | 0.010 |
Why?
|
|
Kalpathy-Cramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|